
    
      This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted
      to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken
      orally daily for 6 months. The study is to be conducted at 2 sites. Up to 18 adult women with
      LAM will be enrolled, and each recruiting site will recruit between 8-12 subjects. The
      protocol will use the following eligibility criteria.
    
  